...
首页> 外文期刊>International immunology. >Tumor cells of non-hematopoietic and hematopoietic origins express activation-induced C-type lectin, the ligand for killer cell lectin-like receptor F1.
【24h】

Tumor cells of non-hematopoietic and hematopoietic origins express activation-induced C-type lectin, the ligand for killer cell lectin-like receptor F1.

机译:非造血和造血起源的肿瘤细胞表达激活诱导的C型凝集素,这是杀伤细胞凝集素样受体F1的配体。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Killer cell lectin-like receptor F1 (KLRF1) is an activating C-type lectin-like receptor expressed on human NK cells and subsets of T cells. In this study, we show that activation-induced C-type lectin (AICL) is a unique KLRF1 ligand expressed on tumor cell lines of hematopoietic and non-hematopoietic origins. We screened a panel of human tumor cell lines using the KLRF1 reporter cells and found that several tumor lines expressed KLRF1 ligands. We characterized a putative KLRF1 ligand expressed on the U937 cell line. The molecular mass for the deglycosylated ligand was 28 kDa under non-reducing condition and 17 kDa under reducing condition, suggesting that the KLRF1 ligand is a homodimer. By expression cloning from a U937 cDNA library, we identified AICL as a KLRF1 ligand. We generated mAbs against AICL to identify the KLRF1 ligands on non-hematopoietic tumor lines. The anti-AICL mAbs stained the tumor lines that express the KLRF1 ligands and importantly the interaction of KLRF1 with the KLRF1 ligand on non-hematopoietic tumors was completely blocked by the two anti-AICL mAbs. Moreover, NK cell degranulation triggered by AICL-expressing targets was partially inhibited by the anti-AICL mAb. Finally, we demonstrate that AICL is expressed in human primary liver cancers. These results suggest that AICL is expressed on tumor cells of non-hematopoietic origins and raise the possibility that AICL may contribute to NK cell surveillance of tumor cells.
机译:杀伤细胞凝集素样受体F1(KLRF1)是在人NK细胞和T细胞子集上表达的活化C型凝集素样受体。在这项研究中,我们表明激活诱导的C型凝集素(AICL)是在造血和非造血起源的肿瘤细胞系上表达的独特KLRF1配体。我们使用KLRF1报告基因细胞筛选了一组人类肿瘤细胞系,发现一些肿瘤细胞系表达KLRF1配体。我们表征了在U937细胞系上表达的假定的KLRF1配体。去糖基化的配体的分子量在非还原条件下为28 kDa,在还原条件下为17 kDa,表明KLRF1配体是同型二聚体。通过从U937 cDNA文库进行表达克隆,我们将AICL鉴定为KLRF1配体。我们生成了针对AICL的单克隆抗体,以鉴定非造血肿瘤细胞系上的KLRF1配体。抗AICL mAb染色表达KLRF1配体的肿瘤细胞系,重要的是,两种抗AICL mAb完全阻断了非造血性肿瘤上KLRF1与KLRF1配体的相互作用。此外,抗AICL mAb可部分抑制表达AICL的靶标触发的NK细胞脱粒。最后,我们证明了AICL在人类原发性肝癌中表达。这些结果表明,AICL在非造血起源的肿瘤细胞上表达,并增加了AICL可能有助于对肿瘤细胞进行NK细胞监视的可能性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号